N5-(2,2-dimethoxy-ethyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine | 760988-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N5-(2,2-dimethoxy-ethyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
• 英文别名: 5-N-(2,2-dimethoxyethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
• CAS: 760988-71-4
• 化学式: C₁₂H₁₅N₇O₃
• 分子量: 305.296
• InChiKey: OSUOSWOJDYOTNI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  N5-(2,2-dimethoxy-ethyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 在 三乙酰氧基硼氢化钠 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N⁵-(2-(4-(3,4-difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
  参考文献：
  名称：

  Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists

  摘要：

  Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been shown to be potent and selective adenosine A(2a) receptor antagonists. We now demonstrate that potent and selective A(2a) receptor antagonists could still be obtained when the arylpiperazines are separated from the triazolotriazine core structure by an ethylenediamine spacer. Selected analogs bearing this triazolotriazine or the related triazolopyrimidine core structure have been found to be orally active in a mouse catalepsy model of Parkinson's disease. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.048
• 作为产物：
  描述：

  氨基乙醛缩二甲醇 、 2-furan-2-yl-5-piperazin-1-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 在 三乙胺 作用下， 以 二甲基亚砜 、 乙腈 为溶剂， 反应 3.0h， 生成 N5-(2,2-dimethoxy-ethyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
  参考文献：
  名称：

  [EN] TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGON ISTS
  [FR] TRIAZOLOTRIAZINES ET PYRAZOLOTRIAZINES ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

  摘要：

  公开号：

  WO2004092170A3

文献信息

• NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS
  申请人：ITEOS THERAPEUTICS S.A.

  公开号：US20200102319A1

  公开（公告）日：2020-04-02

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of proliferative disorders, including cancers.

  本发明涉及式（I）的化合物或其药用可接受盐。该发明进一步涉及将式（I）的化合物用作A2A抑制剂。该发明还涉及将式（I）的化合物用于治疗和/或预防增殖性疾病，包括癌症。
• Triazolotriazines and pyrazolotriazines and methods of making and using the same
  申请人：Vu Chi

  公开号：US20060276475A1

  公开（公告）日：2006-12-07

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A 2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)

  该发明基于发现，化合物(I)的公式具有意外的高亲和力，可用作拮抗剂，用于预防和/或治疗许多疾病，包括帕金森病的A2a腺苷受体。在一种实施例中，该发明涉及公式I的化合物：(I)。
• EP1615930A2
  申请人：——

  公开号：EP1615930A2

  公开（公告）日：2006-01-18
• US7285550B2
  申请人：——

  公开号：US7285550B2

  公开（公告）日：2007-10-23
• [EN] TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES AND METHODS OF MAKING AND USING THE SAME<br/>[FR] TRIAZOLOTRIAZINES ET PYRAZOLOTRIAZINES ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
  申请人：BIOGEN IDEC INC

  公开号：WO2004092170A2

  公开（公告）日：2004-10-28

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson’s disease. In one embodiment, the invention features a compound of formula I: (I)